Unlearn, a San Francisco, CA-based developer of a machine-learning platform that creates Digital Twins used to populate Intelligent Control Arms in clinical studies, raised an approx. $3m Series A extension funding round.
Backers included Eisai, Epic Ventures and Alumni Ventures Group.
In April 2020, Unlearn announced a $12m Series A financing led by 8VC with participation from DCVC, DCVC Bio and Mubadala Capital Ventures. The extension brings the Series A total to $15m.
Led by Charles K. Fisher, Ph.D., founder and CEO, Unlearn has also announced its flagship product, Digital Twins for Alzheimer’s Disease. Unlearn has developed a proprietary AI-model used to generate Digital Twins that are statistically indistinguishable from actual Alzheimer’s Disease patient data. Study sponsors can incorporate a cohort of Digital Twins matched to all of the patients in a given trial to populate Intelligent Control Arms. Intelligent Control Arms can be added prospectively, enabling smaller, more efficient trials, or retrospectively, adding power to trials already enrolling. Unlearn Digital Twins for Alzheimer’s Disease are already being used as part of an ongoing, pivotal trial.